###begin article-title 0
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 260 264 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 422 429 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 442 447 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
CXCL12 is a chemokine that is constitutively expressed in many organs and tissues. CXCL12 promoter hypermethylation has been detected in primary breast tumours and contributes to their metastatic potential. It has been shown that the oestrogen receptor alpha (ESR1) gene can also be silenced by DNA methylation. In this study, we used methylation-specific PCR (MSP) to analyse the methylation status in two regions of the CXCL12 promoter and ESR1 in tumour cell lines and in primary breast tumour samples, and correlated our results with clinicopathological data.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 272 279 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
First, we analysed CXCL12 expression in breast tumour cell lines by RT-PCR. We also used 5-aza-2'-deoxycytidine (5-aza-CdR) treatment and DNA bisulphite sequencing to study the promoter methylation for a specific region of CXCL12 in breast tumour cell lines. We evaluated CXCL12 and ESR1 methylation in primary tumour samples by methylation-specific PCR (MSP). Finally, promoter hypermethylation of these genes was analysed using Fisher's exact test and correlated with clinicopathological data using the Chi square test, Kaplan-Meier survival analysis and Cox regression analysis.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 463 468 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 528 535 524 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 548 553 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
CXCL12 promoter hypermethylation in the first region (island 2) and second region (island 4) was correlated with lack of expression of the gene in tumour cell lines. In the primary tumours, island 2 was hypermethylated in 14.5% of the samples and island 4 was hypermethylated in 54% of the samples. The ESR1 promoter was hypermethylated in 41% of breast tumour samples. In addition, the levels of ERalpha protein expression diminished with increased frequency of ESR1 methylation (p < 0.0001). This study also demonstrated that CXCL12 island 4 and ESR1 methylation occur simultaneously at a high frequency (p = 0.0220).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 128 133 <span type="species:ncbi:9606">women</span>
This is the first study showing a simultaneous involvement of epigenetic regulation for both CXCL12 and ESR1 genes in Brazilian women. The methylation status of both genes was significantly correlated with histologically advanced disease, the presence of metastases and death. Therefore, the methylation pattern of these genes could be used as a molecular marker for the prediction of breast cancer outcome.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 931 932 927 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
Breast cancer development and progression is influenced by intrinsic properties of the tumour cells, as well as by macro-environmental factors. There is an extensive interplay between tumour cells and signalling molecules such as chemokines [1,2]. Chemokine receptors and growth factors have been extensively implicated in the metastatic process of breast cancer [3]. A chemokine-mediated process of tumour cell homing to specific metastatic sites requires an enrichment in the site of metastasis formation for specific chemokines; these chemokines are then able to induce the migration of tumour cells that express the corresponding receptors [3]. CXCL12, formerly known as stromal cell-derived factor-1 (SDF-1alpha), is a CXC subfamily of chemokines that is expressed by stromal cells, including fibroblasts and endothelial cells. CXCL12 is also known to be present in the organs that are target for metastasis in breast cancer [1].
###end p 10
###begin p 11
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 334 341 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 617 618 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
In cancer cells, gene expression is commonly altered due to a combination of genetic and epigenetic events. Aberrant gene silencing in mammalian cells is associated with promoter methylation, and it is known that many regions of the genome are methylated at one or more CpG sites [4,5]. Recent studies have also demonstrated that the CXCL12 gene modulates metastatic potential in breast and colon carcinomas, where it controls its own regulation in an autocrine loop. Epigenetic silencing causes the loss of autocrine expression and results in an imbalance in the expression levels of CXCL12 and its receptor, CXCR4 [6,7].
###end p 11
###begin p 12
###xml 170 173 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 176 177 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 326 327 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 385 389 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 547 549 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 550 552 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 611 616 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 643 650 625 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 695 700 <span type="species:ncbi:9606">women</span>
###xml 877 882 <span type="species:ncbi:9606">women</span>
Sixty percent of primary breast tumours are ERalpha-positive, and two-thirds of advanced breast tumours respond to therapy with anti-estrogens such as tamoxifen (Novaldex(R)) [8]. However, a fraction of tumours that are ERalpha-positive at diagnosis subsequently lose ERalpha expression during the progression of the disease [9]. Hypermethylation of the oestrogen receptor alpha gene (ESR1) is a common occurrence in several specific populations and for workers in a number of occupations; it seems to be a relevant factor for hormonal treatment [10,11]. In this study, we evaluated the methylation patterns of ESR1 and two CpG islands in the CXCL12 gene in breast tumour samples from Brazilian women. This is the first study to report an association between simultaneous DNA methylation of these two genes compared to other prognostic factors in breast cancer among Brazilian women.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Cell Lines
###end title 14
###begin p 15
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 496 497 488 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 338 344 <span type="species:ncbi:9913">bovine</span>
Breast tumour cell lines were all obtained from the Ludwig Institute for Cancer Research, (Sao Paulo, Brazil). The following cell lines were used: MDA-MB-436, MDA-MB-435, MDA-MB-231, MCF-7, PMC42, HB4a (control immortalized normal cells) [12] and HB4aC3.6 [13]. The cell lines were cultured in RPMI 1640 medium [14] containing 10% foetal bovine serum (supplemented with 0.2 mM glutamine, and 40 mug/mL garamycin, 10 mug/mL insulin, if necessary) at 37degreesC in a humidified incubator with 5% CO2.
###end p 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient samples
###end title 16
###begin p 17
###xml 1042 1044 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1156 1157 1154 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
###xml 740 748 <span type="species:ncbi:9606">patients</span>
###xml 899 907 <span type="species:ncbi:9606">patients</span>
Frozen samples of breast tumours (n = 69) used for methylation analysis were obtained from patients treated by primary surgery for breast cancer at the Nossa Senhora das Gracas Hospital, Curitiba, PR, Brazil with institutional approval (Process number 25000.007020/2003-93; CONEP register 7220 opinion number 251/2003). The study included only female patients with invasive breast tumours. All patients gave informed consent for the study to retain and analyse their tissue for research purposes. The ages of the patients ranged from 27 to 84 years (mean 57.8 +/- 14.7). Histological types were either infiltrative ductal carcinoma (IDC) (n = 51, 73.9%) or infiltrative lobular carcinoma (ILC) (n = 18, 26.1%). The lymph node status of the patients was positive (n = 35, 51.5%) or negative (n = 33, 48.5%). Histologic grade was determined according to the modified Bloom-Richardson criteria. Of the patients, 27.6% were Grade I, 47.8% were Grade II and 24.6% were Grade III. TNM staging was done according to official classification methods [15]. Other clinicopathological data (tumour size, local recurrence, metastasis and death) are summarised in Table 1.
###end p 17
###begin p 18
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Clinicopathological features of the 69 patients with primary breast carcinomas according to methylation status of CXCL12 and ESR1 genes
###end p 18
###begin p 19
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 101 102 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 139 141 137 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
Abbreviations: a, data of CXCL12 CpG island-2; b, data of CXCL12 CpG island-4; c, data of ESR1 gene; p, value from statistical analysis chi2 test and Fisher's exact test; M, methylation results; U, unmethylation results; significant data are in bold.
###end p 19
###begin title 20
Immunohistochemistry
###end title 20
###begin p 21
###xml 330 335 <span type="species:ncbi:10090">mouse</span>
###xml 341 346 <span type="species:ncbi:9606">human</span>
###xml 461 467 <span type="species:ncbi:9986">rabbit</span>
Standard immunohistochemical (IHC) detection was performed on sections from archival paraffin embedded breast tumour tissues. Protein expression in malignant breast tissues was detected with specific antibodies against estrogen receptor (ER) and progesterone receptor (PR); clones 1D5 and PgR 636 (DAKO), respectively. Monoclonal mouse anti-human antibodies were pre-diluted and incubated for 18 h at 4degreesC according to the manufacturer's instructions. The rabbit polyclonal antibody against HER2 detection was performed by the HercepTesttrade mark (DAKO CYTOMATION code K5204). In addition, positive and negative controls for each marker were routinely performed during experiments.
###end p 21
###begin p 22
Sections were then processed using the EnVisiontrade markFLEX Target Retrieval Solution (DAKO) according to the manufacture's recommendations. Immunohistochemical staining of the samples was evaluated and scored by two pathologists who were responsible for clinicopathological data. The cutt-of value for ER and PR status values was 10% of cells. Fifty-seven ERalpha-positive tumours were scored based on the number of positive cells present in IHC staining. The slides were scored following the criteria: <10% tumour cells showing nuclear staining scored as 0, 10-30% tumour cells showing nuclear staining scored as 1, 30-50% tumour cells showing nuclear staining scored as 2, >50% tumour cells showing nuclear staining scored as 3.
###end p 22
###begin title 23
RNA extraction and reverse transcription
###end title 23
###begin p 24
###xml 219 225 219 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12-18 </sub>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH </italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 486 488 485 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 552 555 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">aq </italic>
Total RNA was isolated using the TRIzol Reagent (Life Technologies, USA) according to the protocol supplied by the manufacturer. Reverse transcription reactions were performed using 500 ng of DNA-free RNA, an oligo (dT)12-18 primer and Superscript II Reverse Transcriptase (Gibco, BRL). PCR was performed using CXCL12-specific primers, and GAPDH was used as a housekeeping control (Table 2). The PCR was performed in a volume of 20 mul containing 1x PCR buffer (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 200 muM dNTPs, 0.3 muM of each primer and 1 U of Taq Platinum (Invitrogen). The PCR conditions were as follows: 95degreesC for 10 min, 94degreesC for 45 s, the appropriate annealing temperature for 45 s, 72degreesC for 1 min and a final extension of 72degreesC for 5 min. PCR products were resolved on 1% agarose gels and visualised by ethidium bromide staining.
###end p 24
###begin p 25
Summary of primer sequences, used for RT-PCR, nested-PCR and MSP
###end p 25
###begin p 26
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
Abbreviations: M, specific for methylated condition; U, specific for unmethylated condition; (2), primers designed for CpG island 2; (4), primers designed for CpG island 4; ESR1, estrogen receptor gene.
###end p 26
###begin title 27
5-aza-2'-deoxycytidine (5-aza-CdR) treatment
###end title 27
###begin p 28
###xml 110 112 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6 </sup>
###xml 369 376 368 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 450 456 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH </italic>
The cell lines MDA-MB-231, MDA-MB-435 and MDA-MB-436 were analysed using this technique. Cells were plated (106 cells/ml) and treated for 7 days with 1 muM 5-aza-CdR (Sigma Aldrich, Deisenhein, Germany) or left untreated. The medium was changed every day, and no significant cell death was observed. After 7 days of treatment, total RNA was isolated. The expression of CXCL12 in breast tumour cells was analysed by RT-PCR using the housekeeping gene GAPDH as an internal control. PCR products were resolved on 1% agarose gels and visualised by ethidium bromide staining.
###end p 28
###begin title 29
DNA isolation and sodium bisulphite treatment
###end title 29
###begin p 30
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 193 197 193 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
Genomic DNA was prepared from breast cancer cell lines or frozen tumour samples by the phenol/chloroform protocol [16]. They were then subjected to sodium bisulphite treatment using the EpiTect(R) Bisulphite Kit (Qiagen) according to the manufacturer's instructions.
###end p 30
###begin title 31
CXCL12 CpG island methylation analysis
###end title 31
###begin p 32
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
Previous studies used the MSP technique to evaluate the regulation of CXCL12 expression by DNA methylation and in this study we have utilized the designed primers for this region (island 2), as described [7].
###end p 32
###begin p 33
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 794 801 788 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 882 884 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 1030 1032 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1082 1084 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
In an attempt to determine all CpG islands and all potential transcription start sites (TSS) for CXCL12, we first proceeded with the identification of the promoter sequence [17]. The analyses were initiated using an identified RefSeq by GenBank accession number, after which we submitted the gene sequence to a Genome BLAT Search through the UCSC Genome bioinformatics website . We selected 2000 bps of sequence extending from the 5' upstream region to 1000 bps downstream of the region of the TSS. The BLAT program returned a sequence of 5677 bps that was first submitted to the CpGPLOT program from the European Bioinformatics Institute website . This program defines a CpG island as >/= 200 bps of sequence with >/= 50% C + G content and >/= 0.6 CpG observed/CpG expected. The 5677 bps from CXCL12 that we have analysed contained five CpG islands in a region of 3447 bps (Figure 1A). The 5677 bps sequence was also submitted to computational analysis to predict transcription factor binding sites using TESS  and MatInspector [18]. The DNA region we refer to as island 4 (Figure 1A) is positioned next to an estrogen responsive element (ERE) binding site that could be involved in breast cancer. This CpG island was also selected for methylation status analyses in this study.
###end p 33
###begin p 34
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The CpG island of the <italic>CXCL12 </italic>gene</bold>
###xml 35 39 35 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A) </bold>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 362 366 362 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B) </bold>
###xml 652 656 652 656 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C) </bold>
###xml 1087 1091 1087 1091 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D) </bold>
The CpG island of the CXCL12 gene. (A) The CpG island is inside an area from -2594 to +853 (data of the CpGPlot program). The vertical lines correspond to the CpG dinucleotides. The numbers above correspond to the distance in relation to the +1 (TSS). The area considered with promoter activity is outlined and it corresponds to the position -1010 to +122 [22]. (B) Twenty-seven dinucleotides are represented in the figure and positioned in scale. Its localization is signaled below in the figure and the distance in relation to the +1 (TSS). The ERE factor binding is located 19 nucleotides upstream to the CpG island 4 in nucleotides -1900 to -1918. (C) Twenty-seven dinucleotides are numbered in agreement with the sequence. The open circles represent the unmethylated dinucleotides while the dark portion represents the percentage of methylation. On the right side methylation pattern are represented according to data of RT-PCR and the absolute percentage value. The MSP primers for the condition M (methylated) and U (unmethylated) for this island are located below in the figure. (D) Representative examples of sequenced tumours. On the right the methylation percentage of three primary tumours is represented. Global % is the number of methylated CpGs divided by the total analyzed.
###end p 34
###begin p 35
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
Island 4 was amplified from bisulphite-treated DNA samples using a nested-PCR amplification protocol. The two sets of primers were used for the nested reactions at their appropriate annealing temperatures, and are shown in Table 2. The first PCR reactions were performed as described below: 1 cycle of 95degreesC for 10 min, 94degreesC for 3 min, the appropriate annealing temperature for 3 min, 72degreesC for 2 min; 5 cycles of 94degreesC for 3 min, annealing temperature for 3 min, 72degreesC for 2 min; 35 cycles of 94degreesC for 1 min, annealing temperature for 1 min, and 72degreesC for 5 min. Amplified products were purified using the Qiaquick Gel Extraction Kit (Qiagen) and cloned into a pCR2.1 cloning vector (Invitrogen). Eight clones were sequenced for each cell line using the universal or reverse primers. DNA sequencing reactions were performed using Big Dye Terminator technology (Applied Biosystems) on an ABI 377 sequencer (Applied Biosystems) according to the manufacturer's instructions. One hundred percent methylation was obtained if a methylated cytosine in the CpG dinucleotides was present in eight sequenced clones. The methylation percentage for each tumour cell line (global methylation pattern) was calculated by dividing the number of methylated CpG dinucleotides by the total number of CpGs analysed.
###end p 35
###begin title 36
Methylation-specific PCR (MSP)
###end title 36
###begin p 37
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 231 238 231 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 510 516 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 533 537 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 546 548 545 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 612 615 609 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">aq </italic>
###xml 972 973 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1049 1051 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1138 1139 1111 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
Methylation-specific PCR was performed as previously described [19] and the CXCL12 primer sequences for island 2 [7] can be visualized in the Table 2. gDNA from the primary breast tumours was bisulphite-modified and amplified with CXCL12 primers specific for methylated (M) and unmethylated (U) DNA. Analysis of methylation of the ESR1 promoter was performed using the set of primers described by Li et al. [20]. PCR reactions were performed with 1 muL of modified DNA, 1x PCR Buffer (Invitrogen), 1.5 mM (for CXCL12) or 2.5 mM (for ESR1) of MgCl2 (Invitrogen), 200 muM dNTPs, 0.3 muM of each primer and 1 U of Taq Platinum (Invitrogen). The PCR protocol was 95degreesC for 10 min; 38 cycles of 94degreesC for 45 s, the appropriate annealing temperature for 30 s and 72degreesC for 45 s, followed by a final extension of 72degreesC for 5 min. DNA modification was confirmed by a nested-PCR reaction with a set of primers for a previously described satellite region (Table 2). This reaction was used as a control for bisulphite modification quality [21]. This PCR reaction, the nested-PCR and temperature conditions are described in Table 2. The amplification products were separated on 2% agarose gels and stained with ethidium bromide.
###end p 37
###begin title 38
Statistical analysis
###end title 38
###begin p 39
###xml 86 108 86 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Chicago, Illinois, USA</italic>
###xml 274 276 274 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 419 422 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th </sup>
The statistical analysis was carried out using SPSS program (version 16.0, SPSS Inc., Chicago, Illinois, USA). Associations between specific clinicopathological parameters were analyzed using Chi square test and Fisher's exact test. Statistical significance was assumed for p < 0.05. The overall survival was calculated from the time of diagnoses of disease to the occurrence of death. Survival data were censored on 30th June, 2009, which was the date in which the survival data were correlated with the death registry for the last time of a means of 91 months after onset of the disease. Kaplan-Meier estimates are presented for the survival functions, and differences in survival were analyzed using the log rank test. Multivariate analysis was conducted with a backward application of Cox proportional hazards regression analysis was used to estimate hazards ratio (HR) and 95% confidence intervals (95% CI) for overall survival and metastasis-free survival. All covariates with p < 0.25 were retained in the final model.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
CXCL12 expression in breast tumour cell lines
###end title 41
###begin p 42
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 141 148 141 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2 </italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2A</xref>
###xml 378 385 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 520 527 520 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 601 607 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2A</xref>
###xml 708 709 708 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
We first analysed the CXCL12 expression pattern in seven breast tumour cell lines using RT-PCR. A transcript of 383 bps corresponding to the CXCL12 gene was detected in the less aggressive carcinoma cell lines MCF-7 and PMC42, in the normal cell line HB4a and in the modified normal cell line HB4aC3.6 with ERBB2 overexpression (Figure 2A). In contrast, no detectable levels of CXCL12 expression were observed in the highly aggressive tumour cell lines MDA-MB-435, MDA-MB-436 or MDA-MB-231. To definitively determine if CXCL12 expression was, in fact, lost, all analyses were repeated at least twice. GAPDH expression was detected in all samples (Figure 2A). These data are in agreement with the literature [6], except in the case of the normal cell lines and the tumour cell lines MDA-MB-436 and PMC42, where such data have not been previously described.
###end p 42
###begin p 43
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 0 122 0 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>CXCL12 </italic>expression in breast normal and tumour cell lines and expression after 5-aza-2'-deoxycytidine (5-aza-CdR) treatment</bold>
###xml 124 128 124 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A) </bold>
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH </italic>
###xml 256 260 256 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B) </bold>
###xml 260 267 260 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 480 487 480 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 509 510 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
CXCL12 expression in breast normal and tumour cell lines and expression after 5-aza-2'-deoxycytidine (5-aza-CdR) treatment. (A) The bands represent positive results for CXCL12 expression (383 bps) and GAPDH gene was used as housekeeping control (296 bps). (B) CXCL12 expression evaluation after 5-aza-CdR treatment in MDA-MB-435, MDA-MB-436 and MDA-MB-231 cell lines. The cell lines named Mock were not treated, and those named 5-aza-CdR were treated showing the re-expression of CXCL12 on these cell lines. H2O was used as negative control and MM 100 bp was used as a molecular weight marker.
###end p 43
###begin title 44
CXCL12 silencing by DNA methylation
###end title 44
###begin p 45
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 321 328 321 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2B</xref>
To confirm the epigenetic transcriptional silencing of CXCL12, we treated the MDA-MB-435, MDA-MB-436 and MDA-MB-231 breast tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR). The expression of CXCL12 was restored in MDA-MB-435 cells upon treatment as previously observed [6]. Expression of CXCL12 was also restored in MDA-MB-231 cells, but not in MDA-MB-436 cells (Figure 2B).
###end p 45
###begin p 46
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1206 1208 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 1278 1285 1278 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
The CpGPlot program analysis of 5677 bps of the 5' region of the CXCL12 gene identified five putative islands in the CXCL12 promoter region. The CpG island is positioned in an area extending from -2594 to +853 (Figure 1A). In this region, five distinct CpG-rich regions were identified in the positions +512 to +853 (island 1), -840 to +506 (island 2), -1118 to -893 (island 3), -1872 to -1575 (island 4) and -2594 to -2323 (island 5). The region comprised of island 2 studied in the breast and colon carcinomas [6,7] was -493 to +168 relative to the TSS and promoter activity was found in the region from -1010 to +122 [22]. The search for transcription factor binding sites by computational analysis revealed eight oestrogen responsive element (ERE) consensus sites, which are defined as 13 bps perfect palindromic inverted repeats with a 3 bps spacing of variable bases (n) 5'GGTCAnnnTGACC 3' [23]. Five of these sites are very distant from the TSS, two are inside island 2 and the essential GACC sequence is absent. Only one site with the sequence aGctgctggGACC (capital letters for those that match with the consensus), which lies 19 bps away from island 4, might be an oestrogen-binding site (Figure 1B). Therefore, we complemented our tumour sample analysis with MSP for CXCL12 CpG island 4.
###end p 46
###begin p 47
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1C</xref>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 575 581 575 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1C</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2A</xref>
###xml 924 931 924 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2B</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1487 1489 1487 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
Sodium bisulphite sequencing was carried out on a 297 bps DNA fragment containing 27 CpG dinucleotides (-1872 to -1575) (Figure 1B). We analysed the methylation pattern of eight independent alleles (eight clones) from HB4a and HB4aC3.6 normal cell lines, as well as the PMC42, MCF-7, MDA-MB-436, MDA-MB-435, MDA-MB-231 breast tumour cell lines. The methylation pattern varied among the different cell lines as shown in Figure 1C. The CXCL12-negative cell lines, MDA-MB-436 (71%) MDA-MB435 (84%) and MDA-MB-231 (78%) showed CpG dinucleotide hypermethylation. In contrast, the CXCL12-positive cell lines, HB4a (11%), HB4aC3.6 (4%), PMC42 (12%) and MCF-7 (5%), had lower levels of CpG dinucleotide methylation (Figure 1C). These results were in agreement with our expression analysis (Figure 2A). On the other hand, the breast tumour cell line MDA-MB-436 had a dense area of methylated DNA and did not regain expression of the CXCL12 gene when cultured with the demethylating agent 5-aza-CdR (Figure 2B). The importance of DNA methylation in cancer has been well established [24], and the focus in the field is now changing to include the mechanisms by which other chromatin modifications play a role in cancer development. Among these changes are the covalent modifications of histones that can control gene activity. Histone acetylation and methylation of specific lysine residues, such as lysine 9 in histone H3 or lysine 27 in histone H3, clearly participate in the silencing of genes [25].
###end p 47
###begin p 48
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1D</xref>
We also evaluated the CpG dinucleotide sequence for island 4 in the primary breast tumour samples 1, 3 and 8 (Figure 1D). These samples were chosen from the MSP data analysis, and we have confirmed the pattern that was described.
###end p 48
###begin title 49
MSP analysis in breast tumour cell lines
###end title 49
###begin p 50
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1C</xref>
###xml 211 218 211 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 376 383 376 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3A</xref>
###xml 627 634 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 717 724 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3A</xref>
Dinucleotides 4 and 5, and 21-24, which were chosen for the design of methylation-specific PCR (MSP) primers, lie within a region that is differentially methylated (Figure 1C). The MSP technique was tested with CXCL12 (island 2 and island 4) and ESR1 genes in DNA from the tumour cell lines in order to confirm the results from RT-PCR and data from the literature (ESR1). The CXCL12 MSP results from breast tumour cell lines were identical for the two islands (Figure 3A). The MDA-MB-436, MDA-MB-435 and MDA-MB-231 breast tumour cell lines showed methylation of the two islands, which is in agreement with the observed lack of CXCL12 expression. In contrast, the HB4a, HB4aC3.6, MCF-7 and PMC42 cell lines expressing CXCL12 showed no methylated bands (Figure 3A).
###end p 50
###begin p 51
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>CXCL12 </italic>and <italic>ESR1 </italic>methylation analyses of breast normal and tumour cell lines and MSP in primary breast tumours</bold>
###xml 111 115 111 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A) </bold>
###xml 300 307 300 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 324 325 324 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 378 382 378 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B) </bold>
###xml 605 610 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 731 738 731 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 752 757 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 879 883 875 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
CXCL12 and ESR1 methylation analyses of breast normal and tumour cell lines and MSP in primary breast tumours. (A) MSP was performed using bisulphite treated DNA with primers that recognize methylated promoter only. The bands represent positive results for the methylation in the islands 2 and 4 for CXCL12 and ESR1 genes. H2O was used as template in the negative control (NC). (B) Nine of sixty-nine representative samples are included in the figure. Tumour samples were subjected to the MSP reaction, confirming the standardization done with the cell lines for the methylated condition. The results for ESR1 showed promoter methylation in the samples 1 to 7 and 9. The tumour 1 presented both islands negative for methylation of CXCL12 gene; however ESR1 methylation was present even thought this sample is ERalpha positive. The tumour 8 represented a sample with unmethylated ESR1. The lanes 1, 3 and 8 were representative sequenced samples after bisulphite treatment (see Figure 1D).
###end p 51
###begin p 52
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3A</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
The ESR1 MSP results showed hypermethylation in the MDA-MB-436, MDA-MB-435 and MDA-MB-231 breast tumour cell lines as well as in the HB4aC3.6 normal cell line. The HB4a normal cell line and the MCF-7 and PMC42 breast tumour cell lines did not show any methylated bands (Figure 3A). These data corroborate the literature [10,26] except in the case of cell lines MDA-MB-436, PMC42 and HB4aC3.6, which have not been previously described.
###end p 52
###begin p 53
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 127 134 127 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
In this work, we did not evaluate normal breast tissue, but Zhou et al. [27] used twenty normal samples and all of them showed CXCL12 expression without methylation, which is in agreement with a possible tumoral methylation specificity observed in our results.
###end p 53
###begin title 54
MSP analysis in primary breast tumours
###end title 54
###begin p 55
The MSP assay was subsequently used to analyse primary breast tumour samples. All samples showed the band corresponding to the unmethylated state for islands 2 and 4 (data not shown). Based on these results, we can conclude that the samples have cellular heterogeneity due to the presence of normal tissue or infiltrating lymphocytes.
###end p 55
###begin p 56
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3B</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3B</xref>
###xml 279 286 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 311 313 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 413 420 413 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
For the methylated condition, nine representative tumour samples are shown (Figure 3B). Of all the samples tested (69), only four were methylated at both islands, and three of these samples methylated at both genes (Figure 3B). Moreover eighteen samples were methylated in both, CXCL12 island 4 and ESR1 genes (p = 0.0220). This finding indicates a strong correlation between the promoter methylation of ESR1 and CXCL12 island 4. In other words, methylation of the ESR1 promoter could be involved in directing the methylation of island 4 (see more details in discussion).
###end p 56
###begin p 57
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3B</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1D</xref>
We also wanted to confirm that the presence or absence of island 2 or island 4 methylation observed in MSP (Figure 3B) was not just a PCR artefact. Therefore, we sequenced island 4 isolated from tumour samples 1, 3 and 8 (representative for banding pattern). Island 4 displayed 6% methylation in samples 1 and 3, and 89% methylation in sample 8 (Figure 1D). These results are in agreement with the PCR bands observed in the MSP.
###end p 57
###begin title 58
###xml 73 80 <span type="species:ncbi:9606">patient</span>
The correlation between CXCL12 and ESR1 promoter methylation status with patient clinicopathological data
###end title 58
###begin p 59
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1a</xref>
###xml 319 326 319 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1b</xref>
###xml 529 531 529 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 554 556 554 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 577 579 577 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 918 920 918 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 1138 1143 1138 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1147 1153 1147 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 1178 1183 1178 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1184 1186 1184 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1200 1207 1200 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 1217 1219 1217 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4A</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4B</xref>
###xml 1319 1324 1319 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1328 1335 1328 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 1355 1357 1355 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4C</xref>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4D</xref>
###xml 1534 1541 1534 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 1554 1559 1554 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1761 1762 1761 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 1819 1821 1819 1821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1905 1906 1905 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 1959 1961 1959 1961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 2010 2015 2010 2015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 2060 2064 2060 2064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = </italic>
###xml 2114 2121 2110 2117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 2134 2139 2130 2135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 2146 2148 2142 2144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 2158 2162 2154 2158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = </italic>
###xml 2173 2175 2169 2171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 2441 2448 2433 2440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 2461 2466 2453 2458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 2514 2521 2506 2513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 2277 2285 <span type="species:ncbi:9606">Patients</span>
###xml 2407 2415 <span type="species:ncbi:9606">patients</span>
The correlation between the CpG islands of CXCL12 and ESR1 methylation and the clinicopathological parameters of our samples are shown in Table 1. For island 2, CXCL12 methylation was observed in ten of 69 (14.5%) samples and was not significantly associated with any clinicopathological data (Table 1a). For island 4, CXCL12 methylation was observed in 37 of 69 (54%) samples. The clinicopathological parameters are shown in Table 1b and hypermethylation in this region was significantly associated with histological grade SBR (p = 0.0180), metastasis (p = 0.0008) and death (p = 0.0019). These results suggested that CpG island 4 might be important as a factor for poor prognosis of disease. In order to test this hypothesis we evaluated all of the clinicopathological data for their prognostic value in a univariate analysis for overall survival (OS) and metastasis-free survival (MFS) using Kaplan-Meier analysis (p value for log rank test). The overall survival (OS) was significantly worse for many clinicopathological parameters, which are shown in additional file 1. The graphical results for OS and MFS are shown in Figure 4 for ESR1 and CXCL12. The OS correlated with ESR1 (p = 0.0009) and CXCL12 island 4 (p = 0.0071) methylation (Figure 4A and 4B respectively). The metastasis-free survival correlated with ESR1 and CXCL12 island 4 (for both, p < 0.0001) (Figure 4C and 4D, respectively). The Kaplan-Meier analysis showed that the overall survival and metastasis-free survival were significantly shorter when silencing of CXCL12 island 4 and ESR1 occurred by gene hypermethylation. The effects of the covariables on OS and MFS were examined in the Cox proportional hazard regression model. The results for the univariate analysis are shown in Table 3. In the multivariate analysis, all variables presenting p < 0.2 from the univariate analysis were selected to build the multiple model (Table 3). For overall survival, the presence of metastasis (p = 0.0022) was considered a prognostic factor and ESR1 hypermethylation showed a statistical trend (p = 0.0555). Besides ERalpha, the hypermethylation of CXCL12 island 4 and ESR1 genes (p = 0.0302, p = 0.0089 and p = 0.0046, respectively) was considered an independent prognostic factor for metastasis-free survival. Patients with ERalpha protein present had the lowest risk of metastasis development (HR 0.3343; 95% CI 0.1247-0.8963). Otherwise, patients with methylation at both CXCL12 island 4 and ESR1 genes had a risk of developing metastasis, with CXCL12 island 4 having the highest risk (HR 7.1355; 95% CI 1.6480-30.8958).
###end p 59
###begin p 60
Time to breast cancer progression in relation to clinicopathological characteristics: Cox proportional hazards model
###end p 60
###begin p 61
###xml 171 176 <span type="species:ncbi:9606">Human</span>
Abbreviations: HR, hazard ration; CI, confidence interval; SBR, Scarff-Bloom-Richardson classification; ERalpha, estrogen receptor alpha; PR, progesterone receptor; HER2, Human Epidermal growth factor Receptor-type 2. Statistical significance are in bold. * Variables that were not significant at Cox regression analysis.
###end p 61
###begin p 62
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan-Meier curves for time to breast cancer progression according to <italic>CXCL12 </italic>methylation status</bold>
###xml 158 162 158 162 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A) </bold>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 180 184 180 184 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B) </bold>
###xml 184 191 184 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 252 256 252 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C) </bold>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 275 276 275 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 278 285 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 359 361 359 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
Kaplan-Meier curves for time to breast cancer progression according to CXCL12 methylation status. Kaplan-Meier estimates are shown for overall survival using (A) ESR1 methylation, (B) CXCL12 island 4 methylation, and for metastasis-free survival using (C) ESR1 methylation, (D) CXCL12 island 4 methylation. Symbols on the graph lines represent censored data; p values are given for log rank tests.
###end p 62
###begin p 63
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1c</xref>
###xml 221 223 221 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 247 249 247 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 284 286 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 356 358 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 381 383 381 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 404 406 404 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 589 594 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1040 1041 1032 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
###xml 1192 1194 1184 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 1225 1226 1217 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
ESR1methylation was observed in 28 of 69 (41%) tumour samples (Table 1c) and was not significantly associated with age, HER2 or progesterone receptor status, recurrence or histological type. On the other hand, the stage (p = 0.0003), tumour size (p = 0.0029), histological grade SBR (p = 0.0011), lymph node status (p = 0.0288), oestrogen receptor status (p = 0.0054), metastasis (p < 0.0001) and death (p = 0.0105) were significantly associated with ESR1 gene methylation. Statistical analyses demonstrated a correlation between the intensity of ERalpha IHC staining and the frequency of ESR1 promoter methylation. Nine out of eleven (82%) ERalpha-negative cases were hypermethylated. Based on the results from the immunohistochemical analyses, it should be noted that of the samples scored as 0, 15 out of 25 (60%) were methylated; of the samples scored as 1, 8 of the 22 (36%) were methylated; of the samples scored as 2, 5 of the 16 (31%) were methylated; and of the samples scored as 3, none of the six samples were methylated (Figure 5). The number of unmethylated and methylated samples for the scores were submitted to a statistical Fisher's exact test, and statistical significance (p < 0.0001) was obtained (Figure 5). This result with ERalpha-negative status could be due to many mechanisms, including epigenetic mechanisms such as DNA methylation silencing.
###end p 63
###begin p 64
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Correlation of <italic>ESR1 </italic>methylation and protein score staining in the immunohistochemical analysis</bold>
###xml 202 207 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 641 643 633 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
Correlation of ESR1 methylation and protein score staining in the immunohistochemical analysis. The statistical data showed the correlation between intensity of ERalpha staining by IHC and frequency of ESR1 promoter methylation. The dark bars denote methylated samples and grey bars unmethylated samples. The samples with ERalpha expression (score 0 to 3, see material and methods) that showed methylation were: scored 0 - 25 with 15 methylated (60%); score 1 - 22 with 8 methylated (36%); score 2 - 16 with 5 methylated (31%), score 3 - 6 samples without methylation. These results show the percentage of samples that were significant with p < 0.0001.
###end p 64
###begin p 65
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
These results suggest that in breast cancer patients, silencing of the CXCL12 island 4 and ESR1 genes by promoter hypermethylation can be used as a complementary marker for metastasis risk assessment.
###end p 65
###begin title 66
Discussion
###end title 66
###begin p 67
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
Breast cancer development and progression is influenced by intrinsic properties of the tumour cells, as well as macro-environmental factors. Extensive interplay exists between the tumour cells and signalling molecules such as chemokines. Muller et al. [3] showed that cancer metastasis is a non-random process; organ selectivity by the tumour cells is largely determined by factors that are expressed in remote organs that eventually turn into preferred sites of metastases. Many reports have demonstrated that chemokines are essential factors for the invasion and survival of tumours [2]. However, many other factors, such as the microenvironment of the breast cancer cells and genetic and epigenetic alterations, might be involved. Epigenetic events in tumours cells have the ability to modulate gene expression and the role of epigenetic alterations in cancer progression has been the focus of increasing interest in recent years [24].
###end p 67
###begin p 68
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 287 294 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 401 408 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 468 470 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 623 630 619 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 850 851 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 872 874 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1131 1133 1127 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1a</xref>
###xml 121 126 <span type="species:ncbi:9606">women</span>
###xml 881 888 <span type="species:ncbi:9606">patient</span>
In this study, we assessed the epigenetic regulation of the CXCL12 and ESR1genes in breast cancer samples from Brazilian women. The regulation of CXCL12 expression by promoter hypermethylation is common in colon carcinoma [7] and breast cancer, suggesting that tumour cells that silence CXCL12 are at a selective advantage for metastasis [6,27]. In another recent study, positive correlations between CXCL12 hypermethylation and ERalpha-negative status were reported [27]. One of our objectives was to verify in our samples the methylation findings obtained in other female populations. We evaluated two CpG islands of the CXCL12 gene. The first (island 2) was hypermethylated in ten of 69 (14.5%) tumour samples. This region had already been analysed by another group that found DNA methylation in five of 15 (33.3%) American breast cancer samples [6]. In another study [25] with patient samples from a Chinese population, it was verified that 33 of 63 (52.4%) tumour samples were hypermethylated in the same region. These different results might be due to population or environmental differences. The results for island 2 (Table 1a) showed that no statistical significance was identified for any of the variables. We still do not know if different populations might possess promoter regions that are variable due to SNPs or other mechanisms that can switch genes off.
###end p 68
###begin p 69
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 898 905 898 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 1027 1034 1027 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1087 1089 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1199 1205 1199 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12</italic>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1301 1308 1301 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
We have also analysed the CXCL12 5' upstream transcription region in more detail and found a second CpG island we refer to here as island 4, which is near a DNA consensus site for transcriptional activation. Island 4 is located 565 bps from the region studied by Garcia-Moruja et al. [22], and we speculate that this region is important for transcriptional regulation. However, Antequera and Bird [28] argue that the importance of CpG islands situated near the TSS is not always obvious, and that new transcripts beginning in CpG islands distant from the main promoter have been found. Island 4 is located 19 bps away from a 5" oestrogen responsive element (ERE) binding site. No data exist to prove that these ERE consensus sequences could be functional. However, Lin et al. [29] demonstrated discernable differences between functional and non-functional ERE sites (1234 sites were found) and the CXCL12 gene was one of the oestrogen-responsive genes identified in microarray experiments. Other studies have demonstrated that CXCL12 might be a target for oestrogen receptor binding [14,30]. We have concluded that the ERE proximal to island 4 could be involved in the transcriptional regulation of CXCL12. This interaction was modelled by Hall and Korack [14], who suggested that oestrogen activates CXCL12 expression. In this model, CXCL12 binds to the cell surface receptor, CXCR4, in a potentially autocrine and/or paracrine (MAPK cascade) manner, resulting in the activation of cell proliferation.
###end p 69
###begin p 70
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1b</xref>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1c</xref>
###xml 438 445 438 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 589 590 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
The MSP results for island 4 (Table 1b) showed a statistical correlation with three variables related to metastasis, reinforcing a probable role for island 4 in the metastatic process. From these variables, we highlight the correlation of island 4 hypermethylation with ESR1 silencing (Table 1c). In order to study this probable correlation, Kaplan-Meier and Cox analyses were performed. These analyses confirm that the silencing of both CXCL12 island 4 and ESR1 genes by DNA hypermethylation and probably the absence of ERalpha, are prognostic factors for metastasis-free survival (Table 3).
###end p 70
###begin p 71
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3B</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 381 388 381 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
The results showed that ESR1 promoter methylation occurred at a higher frequency in samples with methylated CXCL12 island 4 than in samples with methylated island 2 (Figure 3B). In addition, previous studies [9,10,20,31] reported that the ESR1 gene possesses a hypermethylated promoter region. This might explain the correlation found in this study between the hypermethylation of CXCL12 island 4, but not island 2, and the oestrogen receptor negativity. We speculate that these effects are caused by the proximity of the CpG island to an ERE. Curradi et al. [32] observed that the presence of about eight methylated dinucleotides could inhibit transcription because approximately 700 bps of distance is required for chromatin modifications. Therefore, it is possible that the methylation of island 4 could attenuate or even inactivate ERE binding activity.
###end p 71
###begin p 72
###xml 336 339 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 530 531 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 704 706 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 739 744 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 847 849 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 963 965 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 984 986 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1009 1014 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1246 1248 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1315 1318 1285 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGR</italic>
###xml 1517 1522 1483 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1652 1657 1614 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 1782 1789 1740 1747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
On the other hand, several studies have also shown the inverse correlation. The absence of ERalpha could inactivate target genes that possess an ERE site. It is known that 60% of primary breast tumours are ERalpha-positive, and two-thirds of the advanced tumours do not respond to therapy with anti-estrogens such as tamoxifen (Novaldex(R)). However, more than a third of patients do not express ERalpha at the time of diagnosis, and a fraction of tumours that are positive at the time of diagnosis often lose ERalpha expression [9]. Breast tumour cells in which ERalpha is absent cannot be regulated by oestrogen, and endocrine therapy is not an option, resulting in a poorer prognosis. Lapidus et al. [33] showed for the first time that ESR1 is inactivated by CpG island DNA methylation in cell lines and primary breast tumours. The same group [31] also used MSP to show that breast cancers expressing ERalpha had an unmethylated promoter region. Mirza et al. [10] and Zhao et al. [11] detected 66% and 60% ESR1 hypermethylation in Indian and Chinese populations, respectively. Thus, the hypermethylation of ERalpha is commonly seen in several populations and seems to be relevant to hormonal treatment response. According to this, Leu et al. [34] proposed a model suggesting that the progesterone receptor gene (PGR) or another hypothetical target containing an ERE consensus site inside the promoter region becomes hypermethylated and silenced by repressor proteins when ERalpha is not expressed. In other words, ESR1 inactivation and the consequent lack of ERalpha cause all target genes to become susceptible to epigenetic silencing. Apparently, ESR1 gene silencing by promoter hypermethylation and the consequent absence or decrease of ERalpha expression are able to lead to CXCL12 gene silencing by hypermethylation.
###end p 72
###begin p 73
###xml 428 433 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XCL12</italic>
###xml 169 176 <span type="species:ncbi:9606">patient</span>
Consequently, the absence of CXCL12 signals the cells to form metastasis in tumours with a high tumour grade with negative ERalpha status, increasing the probability of patient death. We do not yet know if island 4 hypermethylation could be involved in the chromatin alterations associated with the blockage of ERalpha binding, or if the absence of ERalpha due to epigenetic silencing can contribute to the hypermethylation of CXCL12.
###end p 73
###begin p 74
###xml 157 162 <span type="species:ncbi:9606">women</span>
The results presented here show that epigenetic alterations might play an important role in the downregulation of CXCL12 mRNA in breast cancers in Brazilian women. Our results, together with recent findings, emphasise the importance of the CXCL12/CXCR4 signalling axis in the organ-specific patterns of metastasis. Epigenetic events could regulate other genes involved in the development of breast cancer and could also be used to predict a better prognosis. The results presented here could also be interpreted as a cause of the eventual resistance seen in response to endocrine therapy.
###end p 74
###begin title 75
Conclusions
###end title 75
###begin p 76
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL12 </italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1 </italic>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
Our results have shown, for the first time, a correlation between hypermethylation of CXCL12 island 4 and ESR1 in patients with histologically advanced cancer, the presence of metastases and death. This correlation could be an important factor in prognosis, cancer prevention and treatment of these patients.
###end p 76
###begin title 77
Competing interests
###end title 77
###begin p 78
The authors declare that they have no competing interests.
###end p 78
###begin title 79
Authors' contributions
###end title 79
###begin p 80
###xml 304 311 <span type="species:ncbi:9606">patient</span>
EASR, carried out the experimental data acquisition, performed data analyses and interpretation and drafted the manuscript. AAC critically revised the manuscript. RS was an undergraduated student and helped with sequencing data collection. KB was the biostatistician in the study. EMSFR and IJC provided patient material and clinicopathological data and critically revised the manuscript. FOP critically revised the manuscript and gave equipment support. EMS critically revised the manuscript and suggested experiments. FFC helped in the experimental design and critically revised the manuscript. GK designed and coordinated the study, supplied administrative support and critically revised the manuscript. All authors read and approved the final manuscript.
###end p 80
###begin title 81
Pre-publication history
###end title 81
###begin p 82
The pre-publication history for this paper can be accessed here:
###end p 82
###begin p 83

###end p 83
###begin title 84
Supplementary Material
###end title 84
###begin title 85
Additional file 1
###end title 85
###begin p 86
###xml 100 102 100 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p </italic>
###xml 0 126 0 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Overall (OS) and metastasis-free survival (MFS) probabilities calculated by Kaplan-Meier estimates (<italic>p </italic>value for log rank test)</bold>
Overall (OS) and metastasis-free survival (MFS) probabilities calculated by Kaplan-Meier estimates (p value for log rank test). Kaplan-Meier results for samples.
###end p 86
###begin p 87
Click here for file
###end p 87
###begin title 88
Acknowledgements
###end title 88
###begin p 89
###xml 135 142 <span type="species:ncbi:9606">patient</span>
We thank Roseli Prado, Valter Baura and Julieta Pie for technical assistance. Thanks also to Dr. Rubens Silveira de Lima for providing patient material and clinicopathological data. This work was supported by the Brazilian Research Council (CNPq) and CAPES. FFC is supported by the Maeve McNicholas Memorial Foundation.
###end p 89
###begin article-title 90
The multifaceted roles of chemokines in malignancy
###end article-title 90
###begin article-title 91
Cancer and the chemokine network
###end article-title 91
###begin article-title 92
Involvement of chemokine receptors in breast cancer metastasis
###end article-title 92
###begin article-title 93
DNA methylation patterns and epigenetic memory
###end article-title 93
###begin article-title 94
ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma
###end article-title 94
###begin article-title 95
Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells
###end article-title 95
###begin article-title 96
Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis
###end article-title 96
###begin article-title 97
Epigenetic information and estrogen receptor alpha expression in breast cancer
###end article-title 97
###begin article-title 98
###xml 129 134 <span type="species:ncbi:9606">human</span>
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells
###end article-title 98
###begin article-title 99
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients
###end article-title 99
###begin article-title 100
###xml 112 117 <span type="species:ncbi:9606">women</span>
Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer
###end article-title 100
###begin article-title 101
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 138 142 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct
###end article-title 101
###begin article-title 102
###xml 39 44 <span type="species:ncbi:9606">human</span>
New model of ErbB-2 over-expression in human mammary luminal epithelial cells
###end article-title 102
###begin article-title 103
Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells
###end article-title 103
###begin article-title 104
Rethinking TNM: breast cancer TNM classification for treatment decision-making and research
###end article-title 104
###begin article-title 105
###xml 46 51 <span type="species:ncbi:9606">human</span>
Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene
###end article-title 105
###begin article-title 106
MatInspector and beyond: promoter analysis based on transcription factor binding sites
###end article-title 106
###begin article-title 107
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 107
###begin article-title 108
DNA hypermethylation in breast cancer and its association with clinicopathological features
###end article-title 108
###begin article-title 109
SATR-1 hypomethylation is a common and early event in breast cancer
###end article-title 109
###begin article-title 110
Functional characterization of SDF-1 proximal promoter
###end article-title 110
###begin article-title 111
Anatomy of the estrogen response element
###end article-title 111
###begin article-title 112
The fundamental role of epigenetic events in cancer
###end article-title 112
###begin article-title 113
The epigenetic magic of histone lysine methylation
###end article-title 113
###begin article-title 114
DNA methylation in breast cancer
###end article-title 114
###begin article-title 115
###xml 122 127 <span type="species:ncbi:9606">human</span>
Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas
###end article-title 115
###begin article-title 116
CpG islands as genomic footprints of promoters that are associated with replication origins
###end article-title 116
###begin article-title 117
Whole-genome cartography of estrogen receptor alpha binding sites
###end article-title 117
###begin article-title 118
The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12
###end article-title 118
###begin article-title 119
Mapping of ER gene CpG island methylation-specific polymerase chain reaction
###end article-title 119
###begin article-title 120
Molecular mechanisms of gene silencing mediated by DNA methylation
###end article-title 120
###begin article-title 121
Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors
###end article-title 121
###begin article-title 122
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer
###end article-title 122

